FDA 510(k) Clearance: Predict AI Timelines by Specialty

Getting FDA clearance is the moment a clinical AI startup proves to investors that a big chunk of the risk is gone. But how long it takes to get that clearance is anything but predictable, with timelines swinging wildly from one medical specialty to another. For anyone writing checks in venture capital or running regulatory analysis, knowing these differences is everything for projecting burn rates and figuring out a realistic time-to-market.

The Regulatory Field: A 510(k) Benchmark Across Specialties

Most SaMD (Software as a Medical Device) products, and that includes almost all healthcare AI algorithms, get to market through the FDA’s 510(k) pathway. To do it, you have to prove your device is “substantially equivalent” to a predicate device that’s already cleared. While this is usually faster than a De Novo classification, it can still be a slog with unpredictable review periods. When we dug into historical FDA 510(k) decision data, we saw clear patterns emerge between AI tools for radiology, cardiology, and oncology. Historically, radiology AI has had the smoothest ride through the 510(k) process. There’s just a massive library of existing predicate devices to point to, and the regulatory framework for medical imaging software is already well-established, which speeds things up considerably. A company like Aidoc, a big name in this space, has racked up numerous clearances for its radiology algorithms by building on existing imaging modalities and fitting into established diagnostic workflows. These clearances are often for AI that spots things like intracranial hemorrhage, pulmonary embolism, or incidental findings on CT scans. Having access to strong, well-labeled training and validation datasets, often from large hospital systems, also makes the submission paperwork much simpler. FDA 510(k) public database for radiology AI clearances Cardiology AI, on the other hand, tends to take a bit longer, even with all the rapid development happening. You have plenty of established cardiac imaging modalities (think echocardiography, cardiac MRI, or CT angiography), but the agency often applies more scrutiny because cardiac physiology is so complex and you’re interpreting dynamic data. For instance, an AI algorithm built to automate cardiac function assessment or detect disease (like the ones Cleerly develops for cardiac analysis) needs extremely careful validation against real clinical endpoints. The FDA zeroes in on how an AI diagnosis will actually affect patient care, so submissions demand more extensive clinical performance data, which naturally stretches out the review cycle. Sometimes, the newness of a cardiac AI tool, even when going for a 510(k), can test the definition of “substantial equivalence” and trigger more questions from the agency. Oncology AI is where the timelines really stretch out, particularly for diagnostic and prognostic tools. It consistently shows the longest average 510(k) clearance times of the three. Why? Think about it: cancer is wildly different from patient to patient, the ethical considerations around diagnosis and treatment are heavy, and the AI often has to process a messy mix of data from pathology, genomics, and imaging all at once. AI for tasks like tumor segmentation is getting more common, but the required level of clinical evidence and analytical validation is much higher because a misdiagnosis can have such devastating results. For a really novel oncology AI tool, the lack of a direct predicate device can easily force a company down the De Novo path even if they were aiming for a 510(k), adding even more time to the clock.

Case Studies in Regulatory Navigation

A look at a few companies makes these patterns obvious. Viz.ai, a leader in stroke detection and care coordination, has multiple FDA clearances for its platform. Their success shows what happens when you have a focused clinical application with clear, measurable outcomes that plug directly into existing emergency care pathways. Being able to show their AI cuts down the time-to-treatment for stroke patients gives regulators a concrete clinical reason to say yes. Viz.ai FDA clearance announcements Aidoc’s broad portfolio of cleared radiology AI algorithms is a great example of the efficiency you can get in a well-defined specialty. Their strategy is to build a platform with multiple, distinct algorithms for different radiological findings. This lets them piggyback on existing predicate devices and build on their own proven regulatory track record. This makes the regulatory burn for each new algorithm more predictable, since the foundational QMS (Quality Management System) and regulatory processes are already solid. Cleerly, which focuses on cardiovascular disease, has gotten clearances for its AI-powered analysis of CT angiograms. Their journey shows the complexities in cardiology, where proving the clinical significance of subtle plaque characteristics requires a mountain of validation data. Their clearances prove AI is perfectly viable here, but that depth of evidence needed for such a nuanced diagnostic tool means a longer and more intense data collection and analysis phase before and during the regulatory process.

Implications for Venture Investors

For VCs in healthcare, these different clearance timelines aren’t just interesting, they’re direct inputs for your financial models and investment strategy.

• Burn Rate Projections: Longer review cycles mean higher burn. It’s that simple. An oncology AI startup looking at a 12-18 month 510(k) process needs a much longer runway than a radiology AI company that’s expecting 6-9 months. Investors have to price this into the initial funding and plan for later capital needs.
• Time to Revenue: You can’t really start selling or, more importantly, get payers to cover your product until you have FDA clearance. Any delay in that clearance pushes back your time to revenue and the return on investment. The companies that get funded consistently are the ones with published clinical outcomes and signed payer contracts.
• Regulatory De-risking: Talking to the FDA early, through pre-submission meetings, is one of the best ways to get clear on their expectations and maybe even shorten the review clock. Investors need to dig into a startup’s regulatory plan and the background of its regulatory affairs people. Seeing a coherent 510(k) plan, or a realistic De Novo strategy if needed, takes a huge amount of risk off the table.
• Predicate Device Strategy: Choosing a predicate device isn’t just a technicality, it’s a strategic move. A team that can find a strong, similar predicate will almost always have a smoother 510(k) review. As an investor, you have to understand the team’s predicate strategy, especially for newer AI where finding a good one is tough. The FDA is trying to create more predictable paths for adaptive algorithms with things like the finalized guidance for PCCPs (Predetermined Change Control Plans), but the reality today is that you still get a big advantage from knowing the unwritten rules of your specific clinical specialty.
  

  Methodology and Source Note

  We put this analysis together by digging through the public FDA 510(k) database, reviewing regulatory submission logs, and reading publicly available studies on FDA review timelines for medical devices. We cross-checked the data points on average FDA review times by product code and the number of cleared algorithms per specialty against official FDA publications and reputable industry reports. FDA guidance on 510(k) review process Of course, individual review times will always depend on how clean the submission is and how complex the device is, but the patterns we see across radiology, cardiology, and oncology are solid benchmarks for strategic planning. Knowing these regulatory differences gives you a competitive advantage. The companies that strategically work the FDA system, anticipating and handling the hurdles specific to their clinical domain, are the ones better positioned to get and keep investment, and they’ll be the ones to speed up the adoption of powerful AI in healthcare.